-
-
-
-
-
-
-
JPMorgan Reiterates Overweight Rating on Teva Pharma (TEVA)
-
-
-
-
-
-
-
Medincell’s Partner Teva Provides Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® Commercial Progress
-
-
-
-
-
-
-
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
-
-
-
-
-
-
-
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
-
-
-
-
-
-
-
These 10 stocks are BofA's top ideas for Q4
-
-
-
-
-
-
-
Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023
-
-
-
-
-
-
-
Teva Finalizes Nationwide Opioid Settlement Terms
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

